HomeCompareABT vs SHLX

ABT vs SHLX: Dividend Comparison 2026

ABT yields 2.36% · SHLX yields 60.75%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABT wins by $501.6K in total portfolio value· pulled ahead in Year 6
10 years
ABT
ABT
● Live price
2.36%
Share price
$101.89
Annual div
$2.40
5Y div CAGR
63.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$533.6K
Annual income
$328,772.04
Full ABT calculator →
SHLX
SHLX
● Live price
60.75%
Share price
$15.82
Annual div
$9.61
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.1K
Annual income
$9.66
Full SHLX calculator →

Portfolio growth — ABT vs SHLX

📍 ABT pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABTSHLX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABT + SHLX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABT pays
SHLX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABT
Annual income on $10K today (after 15% tax)
$200.23/yr
After 10yr DRIP, annual income (after tax)
$279,456.23/yr
SHLX
Annual income on $10K today (after 15% tax)
$5,163.96/yr
After 10yr DRIP, annual income (after tax)
$8.21/yr
At 15% tax rate, ABT beats the other by $279,448.02/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABT + SHLX for your $10,000?

ABT: 50%SHLX: 50%
100% SHLX50/50100% ABT
Portfolio after 10yr
$282.8K
Annual income
$164,390.85/yr
Blended yield
58.12%
📊

Analyst Conviction Gap

Where Wall Street is split right now

ABT
No analyst data
Altman Z
4.9
Piotroski
6/9
SHLX
Analyst Ratings
4
Buy
7
Hold
4
Sell
Consensus: Hold
Price Target
$16.00
+1.1% upside vs current
Range: $16.00 — $16.00
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABT buys
0
SHLX buys
0
No recent congressional trades found for ABT or SHLX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABTSHLX
Forward yield2.36%60.75%
Annual dividend / share$2.40$9.61
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR63.2%-50%
Portfolio after 10y$533.6K$32.1K
Annual income after 10y$328,772.04$9.66
Total dividends collected$492.4K$7.3K
Payment frequencyquarterlyquarterly
SectorHealthcareStock

Year-by-year: ABT vs SHLX ($10,000, DRIP)

YearABT PortfolioABT Income/yrSHLX PortfolioSHLX Income/yrGap
1$11,084$384.43$13,738$3,037.63$2.7KSHLX
2$12,510$649.94$16,649$1,949.99$4.1KSHLX
3$14,505$1,118.82$18,919$1,104.34$4.4KSHLX
4$17,499$1,978.53$20,830$586.40$3.3KSHLX
5$22,364$3,640.59$22,590$301.69$226.00SHLX
6← crossover$31,026$7,096.70$24,324$152.89+$6.7KABT
7$48,215$15,016.56$26,103$76.93+$22.1KABT
8$87,182$35,592.30$27,969$38.58+$59.2KABT
9$191,446$98,161.15$29,946$19.32+$161.5KABT
10$533,619$328,772.04$32,052$9.66+$501.6KABT

ABT vs SHLX: Complete Analysis 2026

ABTHealthcare

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Full ABT Calculator →

SHLXStock

Shell Midstream Partners, L.P. owns, operates, develops, and acquires pipelines and other midstream, and logistics assets in the United States. It owns interests in crude oil and refined products pipelines and terminals to transport onshore and offshore crude oil production to Gulf Coast and Midwest refining markets. The company stores and transports crude oil, refined, natural gas, and refinery gas products for various customers, including producers, refiners, marketers, and traders, as well as to other crude oil and refined products pipelines through its pipelines and storage tanks. Shell Midstream Partners GP LLC serves as the general partner of Shell Midstream Partners, L.P. The company was incorporated in 2014 and is headquartered in Houston, Texas. Shell Midstream Partners, L.P. is a subsidiary of Shell Pipeline Company LP.

Full SHLX Calculator →
📬

Get this ABT vs SHLX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABT vs SCHDABT vs JEPIABT vs OABT vs KOABT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.